Outcome and safety of self-expandable metallic stents for malignant colon obstruction: a Korean multicenter randomized prospective study

[1] Jemal A(2010)Cancer statistics, 2010 CA Cancer J Clin 60 277-300

[2] Siegel R(2010)Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2893-2917

[3] Xu J(1976)Mortality and prognosis of obstructing carcinoma of the large bowel Am J Surg 131 36-41

[4] Ferlay J(1992)Management and survival of patients affected with obstructive colorectal cancer Int Surg 77 251-255

[5] Shin HR(2001)Obstructing colonic cancer: failure and survival patterns over a ten-year follow-up after one-stage curative surgery Dis Colon Rectum 44 243-250

[6] Bray F(2008)Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer J Clin Oncol 26 2006-2012

[7] Dutton JW(2009)Oncologic outcomes of self-expanding metallic stent insertion as a bridge to surgery in the management of left-sided colon cancer obstruction: comparison with nonobstructing elective surgery World J Surg 33 1281-1286

[8] Hreno A(2008)Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013-2019

[9] Hampson LG(1999)CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR Eur J Cancer 35 1343-1347

[10] Barillari P(2005)Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer J Clin Oncol 23 3706-3712

[1] Jemal A(2010)Cancer statistics, 2010 CA Cancer J Clin 60 277-300

[2] Siegel R(2010)Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2893-2917

[3] Xu J(1976)Mortality and prognosis of obstructing carcinoma of the large bowel Am J Surg 131 36-41

[4] Ferlay J(1992)Management and survival of patients affected with obstructive colorectal cancer Int Surg 77 251-255

[5] Shin HR(2001)Obstructing colonic cancer: failure and survival patterns over a ten-year follow-up after one-stage curative surgery Dis Colon Rectum 44 243-250

[6] Bray F(2008)Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer J Clin Oncol 26 2006-2012

[7] Dutton JW(2009)Oncologic outcomes of self-expanding metallic stent insertion as a bridge to surgery in the management of left-sided colon cancer obstruction: comparison with nonobstructing elective surgery World J Surg 33 1281-1286

[8] Hreno A(2008)Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013-2019

[9] Hampson LG(1999)CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR Eur J Cancer 35 1343-1347

[10] Barillari P(2005)Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer J Clin Oncol 23 3706-3712